Multiple Myeloma Clinical Trials in Minneapolis, Minnesota

7 studies are recruiting for multiple myeloma in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

   The purpose of this study is to evaluate how well JNJ-79635322 works when compared with teclistamab.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University Of Minnesota Medical Center, Minneapolis, Minnesota

   Locations

   151 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07518186 on ClinicalTrials.gov

2. Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

   This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVH…

   Stage

   Phase 2

   Ages

   Up to 60

   Site

   Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

   Run by

   Masonic Cancer Center, University of Minnesota

   See if you can join NCT03314974 on ClinicalTrials.gov

3. A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

   Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and kidney failure. This is a study to determine the adverse events, change…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Minnesota Oncology - Minneapolis Clinic /ID# 278720, Minneapolis, Minnesota

   Locations

   49 in total

   Run by

   AbbVie

   See if you can join NCT07095452 on ClinicalTrials.gov

4. Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

   This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Minnesota Oncology Hematology, Minneapolis, Minnesota

   Locations

   17 in total

   Run by

   SCRI Development Innovations, LLC

   See if you can join NCT05972135 on ClinicalTrials.gov

5. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

   This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

   Stage

   Not phased

   Ages

   40 and older

   Site

   Allina Health Cancer Institute, Minneapolis, Minnesota

   Locations

   17 in total

   Run by

   Adela, Inc

   See if you can join NCT05366881 on ClinicalTrials.gov

6. IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

   This is an open label, Phase 1/2, first-in-human, multiple ascending dose, and dose-expansion study of IDP-023 administered as a single agent and in combination with or without interleukin-2 (IL-2), and with or without isatuximab, daratumumab or rituximab to evaluate the safety, tolerability and pr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Minnesota, Minneapolis, Minnesota

   Locations

   12 in total

   Run by

   Indapta Therapeutics, INC.

   See if you can join NCT06119685 on ClinicalTrials.gov

7. Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma

   Multiple myeloma (MM) is the second most common hematologic malignancy in adults. The current standard of care for MM patients fit to undergo high dose conditioning chemotherapy is an autologous HCT (autoHCT). Allogeneic HCT (alloHCT) is the only potentially curative therapy available to patients w…

   Stage

   Not phased

   Ages

   Any age

   Site

   Center for International Blood and Marrow Transplant Research, Minneapolis, Minnesota

   Run by

   Center for International Blood and Marrow Transplant Research

   See if you can join NCT03127761 on ClinicalTrials.gov